AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06470048
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ianalumab matching placebo subcutaneous (s.c.) injection as defined in the protocol
Trial: NCT04902131
Drug: A MENOPUR solution for injection in pre-filled pen, 600 IU/0.96 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose cross-over bioequivalence trial
Trial: NCT04902131
Drug: A MENOPUR powder including solvent for solution for injection, 75 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose cross-over bioequivalence trial
Trial: NCT06213506
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of Placebo administered intramuscularly at Day 57 to adults in the Adults_Control group.
Trial: NCT06456346
Drug: Hydroxyurea placebo
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsule placebo
Trial: NCT05798520
Drug: BIIB091
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT05798520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT06640413
Drug: [177Lu]Lu-OncoFAP-23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.7, 7.4, or 11.1 GBq to define the RD
Trial: NCT04947527
Drug: Test varnish
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
Trial: NCT06405139
Drug: Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanoliposomal irinotecan 60mg/m2; Oxaliplatin 85 mg/m2; Capecitabine 800 mg/m2 twice daily, day 1 to 7; repeated every two weeks.
Trial: NCT05211986
Drug: IMM01-STEM
RxNorm normalized name: AKEBIA STEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMM01-STEM is a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules.
Trial: NCT05733390
Drug: JZP541
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral suspension
Trial: NCT05653713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV dose of 0.9% saline
Trial: NCT04947527
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A maximum of 0.2 mL will be applied to the teeth with a dental brush. Test or control varnish will be applied topically 4 times per year following enrollment and at each 3 to 4-month intervals.
Trial: NCT05885542
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind placebo oral solution administered once
Trial: NCT04881240
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a nitrogen mustard derivative. It acts as an alkylating agent that causes cross-linking of DNA strands by binding with nucleic acids and other intracellular structures, thus interfering with the normal function of DNA.
Trial: NCT04921033
Drug: Standart of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Budesonide 9mg/day for mild disease~* Prednisolone 1mg/kg, maximum 40mg/day in decreasing doses (40mg for 4 weeks followed by a fixed taper for 6 weeks) for moderate-to-severe disease for 12 weeks.~* Patients with moderate to severe disease in the steroid group will also receive 2mg/kg azathioprine. The dose of azathioprine will be adjusted according to abnormalities of white blood cell (WBC) count, platelet count, liver function tests (LFTs; i.e. alanine transaminase \[ALT\], aspartate transaminase \[AST\], alkaline phosphatase), lipase, blood urea nitrogen (BUN), and serum creatinine.
Trial: NCT05089227
Drug: treatment intervention
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: for a total of 12 weeks, prophylactic heparin therapy during hospitalization followed by prophylactic oral anticoagulation with apixaban
Trial: NCT05089227
Drug: treatment standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: during hospitalization prophylactic heparin therapy followed by management without prophylactic anticoagulation.
Trial: NCT04814771
Drug: [14C] TS-142
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects received single dose of 7.5 mg of TS-142 containing 20 kBq \[14C\]TS-142 as an oral solution
Trial: NCT05868876
Drug: AK127 Q3W IV infusion ,AK104 10mg/kg Q3W IV infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK127 is administered intravenously according to the frequency Q3W and different dosage of administration at different stages.AK104 is administered intravenously according to the frequency and dosage 10mg/kg Q3W.
Trial: NCT04675983
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT05089084
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile normal saline (0.9% NaCl)
Trial: NCT05407792
Drug: Staphylococcus and Neisseria Tablets
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/ tablet, 4 tablets each time, 3 times a day (Shandong Qilu Pharmaceutical Co., LTD.), the course of treatment was more than 3 months.
Trial: NCT06485232
Drug: Universal BCMA CAR-T; Universal CD19 CAR-T
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal BCMA CAR-T; Universal CD19 CAR-T
Trial: NCT04689828
Drug: ARDT
RxNorm normalized name: CHLAMYDOMONAS REINHARDTII
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered orally on a continuous basis, as per package insert and guidelines
Trial: NCT05070728
Drug: FAI Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yutiq 0.05 mg contains 0.05 mg FA and was designed to deliver FA into the vitreous humor for at least 24 weeks.~Yutiq 0.05 mg was administered to the study eye by injection through the pars plana using a pre-loaded applicator with a 25-gauge needle.
Trial: NCT06354257
Drug: EE/LNG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of EE and LNG is administered on Day 1 of treatment period 1 and one dose of EE/LNG co-administered with GSK3036656 DL 2 is given on Day 15 of treatment period 3.
Trial: NCT06033950
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral placebo.
Trial: NCT06518603
Drug: Caffeine citrate 20mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine citrate 20mg/kg/day given orally once daily for 28 days
Trial: NCT06244303
Drug: manual Tooth Brush + Colgate Total TP (0.454% SnF, 1100 ppm F)
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste, toothbrush \& mouthwash regime
Trial: NCT06244303
Drug: manual toothbrush + Colgate dental cream
RxNorm normalized name: Colgate Dental Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toothpaste + toothbrush
Trial: NCT06652529
Drug: AROG4-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.
Trial: NCT06652529
Drug: AROG4-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AROG4-01 will be administered as IV infusions in biweekly dosing interval. The first dosing day will be Day 1, 28 days cycle.~This study is an open label, Phase 1 dose escalation trial with two expansion cohorts. The study consists of two parts:~* Part A: Dose escalation in patients with advanced solid tumors. Approximately 8 to 20 patients in total will be enrolled in part A, covering up to 6 dose levels.~* Part B: At the dose expansion phase, AROG4-01 two cohorts of ten patients with advanced solid tumor each will be recruited. One cohort of patients with advanced MPM (cohort 1) and a second cohort of patients with other solid tumors (cohort 2).
Trial: NCT04909801
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate oral/parenteral maximum tolerated dose (minimum 15 mg and maximum 25 mg weekly)
Trial: NCT06158490
Drug: JYP0061 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the JYP0061 15 mg group will receive a 15 mg oral tablet of JYP0061 once daily for 12 weeks.
Trial: NCT06158490
Drug: JYP0061 30 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: articipants in the JYP0061 30 mg group will receive a 30 mg oral tablet of JYP0061 once daily for 12 weeks.
Trial: NCT06158490
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the placebo group will receive a matching placebo tablet once daily for 12 weeks.
Trial: NCT06662942
Drug: StrataMGT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.
Trial: NCT06662942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is a sterile, transparent, water-soluble lubricating jelly that is not silicone-based. It will be applied topically to the vulvar skin.
Trial: NCT06680531
Drug: YZJ-1139 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YZJ-1139 tablets are administered orally single dose
Trial: NCT04872543
Drug: ASTX727
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.
Trial: NCT04768426
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 administered on Days 1 to 14 of 21-day treatment cycles, for 8 cycles.
Trial: NCT05327114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered intravenously.
Trial: NCT05489211
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT05489211
Drug: Leucovorin LV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as an IV
Trial: NCT06465823
Drug: Bumetanide
RxNorm normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the Bumetanide group will be treated for 3 months with a dose of 0.02 mg/kg twice a day, oral administration. It will be labeled (pre-printed and indistinguishable) with the randomization number and site number and will be delivered in separate blocks during the first, second and fourth appointment.~The patients will start the treatment with half of the full target dose during the first week:~* If the target dose is 0.5mg BID, only the morning dose will be administrated.~* If the target dose is 1.0 mg BID the dose will be 0.5 mg BID.~* If the target dose is 1.5mg BID, the morning dose will be 1.0 mg, the evening dose will be 0.5 mg.~* If the target dose is 2.0 mg BID the dose will be 1.0 mg BID The patient will continue with the full dose starting from Visit 2 after 1 week of dosing.
Trial: NCT06465823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control (placebo) group will be given placebo for 3 months twice a day, oral administration. The Placebo tablets will be visually indistinguishable from Bumetanide and packaged as Bumetanide. The placebo will be labeled (pre-printed and indistinguishable) with the randomisation number and site number and will be delivered in separate blocks during the first, second and fourth visits.
Trial: NCT05574114
Drug: Conditioning chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day -5 to -3: Patients will receive standard of care lymphodepleting chemotherapy
Trial: NCT05549180
Drug: BIKTARVY 50Mg-200Mg-25Mg Tablet and Dovato placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients randomized to experimental arm will be randomized to Biktarvy + Dovato placebo
Trial: NCT05549180
Drug: Dovato 50Mg-300Mg Tablet + Biktarvy placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients randomized to comparador arm will be randomized to Dovato + Biktarvy placebo
Trial: NCT06710379
Drug: ADRX-0405
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody Drug Conjugate targeting STEAP1
Trial: NCT04934527
Drug: Cytotect
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The inclusion visit is conducted by the investigating nephrologist and the patient will receive their first infusion of anti-CMV Ig.~Patients with positive CMV serology at transplantation will receive 6 infusions of 100 units per kilogram of body weight every 15 days with the first injection on the day of transplantation, i.e. at visits D0, S2, S4, S6, S8 and S10. CMV infection will be monitored by quantitative PCR on whole blood every week during 3 months and then every 2 weeks until 4 months and then at months 5 and 6, 9 and 12.
Trial: NCT06710327
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive a saline solution, which is a sodium chloride (0.9%) IV infusion, identical in appearance to the TXA solution. The saline is administered as a single 1 gram-equivalent volume intravenous (IV) push, delivered immediately before the Aquablation therapy commences. This singular administration matches the frequency and timing of the TXA intervention to ensure uniformity across both study groups, maintaining the blinding of the study.
Trial: NCT06708624
Drug: FYB201 0.5 mg (0.05 mL of 10 mg/mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVT administration of FYB201 in a PFS
Trial: NCT04883619
Drug: Standard-of-care treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care treatment including MMF or MPA and glucocorticoids will be administered intravenously through Week 52.
Trial: NCT06049082
Drug: KB408 (Nebulization)
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized solution of KB408, a replication-defective HSV-1 vector expressing full length human SERPINA1
Trial: NCT05191563
Drug: HCP1904-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period.
Trial: NCT05191563
Drug: RLD2006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period.
Trial: NCT05191563
Drug: RLD2001-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take it once per period.
Trial: NCT05883241
Drug: 2.5% Diclofenac Patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pain relief-gel worn during treatment via SAM patch.
Trial: NCT05367492
Drug: Double Blind Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For participants 16-17 years old, ≤ 55 kg:~* 0.5 mg once daily for 7 days, then~* 0.5 mg twice daily for 11 weeks~For participants 16-17 years old, \>55 kg:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks~For participants 18+ years old, regardless of weight:~* 0.5 mg once daily or 3 days,~* 0.5 mg twice daily for 4 days~* 1.0 mg twice daily for 11 weeks
Trial: NCT05237388
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baricitinib placebo pill
Trial: NCT03867851
Drug: IBsolvMIR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study drug IBsolvMIR
Trial: NCT03867851
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clinical praxis
Trial: NCT04817618
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)
Trial: NCT05824312
Drug: Tyrosine kinase inhibitor drugs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TKI drugs were used at least 8 weeks. Imaging exam would be taken every four weeks.
Trial: NCT05727618
Drug: Pituitrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The specification of posterior pituitary injection is 1ml/6U, diluted with normal saline to 0.5u/ml, and injected by intravenous pump at the rate of 0.04u/ (kg · h).
Trial: NCT05727618
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of normal saline at the same dose and speed
Trial: NCT05306379
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dose 40 mg
Trial: NCT05929599
Drug: 0.9% NaCl physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Trial: NCT05737121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive placebo for VNX001
Trial: NCT05737121
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alkalinized heparin sodium
Trial: NCT05406362
Drug: VAD044 Part II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules to be taken once daily for 12 months
Trial: NCT05227742
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive inert placebo once per week for 5 weeks.
Trial: NCT05657925
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be identical in appearance to the active treatment pill
Trial: NCT06467942
Drug: Chinese medicine and Lactobacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combined drug group
Trial: NCT04584125
Drug: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A wavelength of 365 nm ultraviolet A light will be used to direct 5.4 J/cm2 using a beam diameter of 9.5mm to treat the de-epithelialized corneal surface of a donor cornea for 30 minutes. Every 2 minutes, the UV light will be used while another drop of riboflavin is applied on top of the donor cornea.
Trial: NCT04584125
Drug: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The corneal tissue for the control arm will be treated the same as the crosslinked tissue except that it will not be exposed to ultraviolet light. The donor cornea will be placed on an artificial anterior chamber maintainer and the epithelium will be removed mechanically. Riboflavin solution (0.1% riboflavin and 20% dextran supplied in a sterile, single-dose container) will be applied to the cornea every 2 minutes for 30 minutes.
Trial: NCT04790240
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remdesivir (Veklury), Colchicine, anti-SARS-CoV-2 monoclonal antibodies, bamlanivimab, Casirivimab \& Imdevimab.
Trial: NCT05974748
Drug: Propolis 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In group B, a 20% hydroalcoholic propolis solution of 3 milliliters will be used to irrigate each canal, between each instrument.
Trial: NCT06150378
Drug: Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients that receive an injection with corticosteroid
Trial: NCT05707936
Drug: Heparin Flush (1000 USP, 10ml)
RxNorm normalized name: heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin Flush (1000 USP, 10ml)
Trial: NCT06482593
Drug: Zinc-Oxide Eugenol Sealer
RxNorm normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zinc oxide-eugenol sealers have a slow setting time, shrinkage while setting, solubility, and can discolour tooth structure. This sealer group has an advantage in terms of antibacterial activity.It will absorb if extruded into the periradicular tissues.
Trial: NCT06482593
Drug: Bio-C Sealer
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-C® Sealer is a ready-to-use, bioceramic root canal sealer with biologically active ingredients to seal and heal the root canal space. Bio-C Sealer's mechanical and physical properties make it easy to manipulate and seal the canals, while its biological properties and high pH ensure safety and treatment success.
Trial: NCT06428682
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group will receive same volume equivalent of saline intravenously at the time of their surgery.
Trial: NCT03532958
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose volume consistent with weight-based dosing of BNZ-1
Trial: NCT04940767
Drug: Amzeeq 4% Topical Foam
RxNorm normalized name: Amzeeq 4% Topical Foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMZEEQ® is a topical lipophilic foam containing 4% minocycline that was approved in the US for the treatment of acne vulgaris in 2019
Trial: NCT04767620
Drug: Rugdenzengsheng No. 1 prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.